darusentan darusentan darusentan (lu-135252; hmr-4005) is an endothelin receptor antagonist. gilead colorado, a subsidiary of gilead sciences, under license from abbott laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension. darusentanclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status investigational pharmacokinetic datametabolismhepaticelimination half-life12.5 hoursidentifiers iupac name (2s)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid cas number171714-84-4 ypubchem cid177236iuphar/bps3508chemspider154336 nunii33jd57l6rwchemblchembl23261 ncomptox dashboard (epa)dtxsid1057664 echa infocard100.126.841 chemical and physical dataformulac22h22n2o6molar mass410.426 g·mol−13d model (jsmol)interactive image smiles coc1=cc(=nc(=n1)o(c(=o)o)c(c2=cc=cc=c2)(c3=cc=cc=c3)oc)oc inchi inchi=1s/c22h22n2o6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19h,1-3h3,(h,25,26)/t19-/m1/s1 nkey:fejvsjialltfrp-ljqanchmsa-n n ny (what is this?) (verify) in june 2003, myogen licensed the compound from abbott for its application in the cancer field. in may 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase iii trial was initiated in subjects who had completed the maintenance period of the dar-312 study, but was terminated because the study did not reach its primary endpoints.